A Philadelphia jury hit Janssen Pharmaceuticals with a $70 million verdict in a case over the antipsychotic drug Risperdal. The case, which was the fifth to go to trial from Philadelphia’s Risperdal-related mass tort program, resulted in the largest award out of that program by a factor of nearly 30.
The unanimous verdict in A.Y. v. Janssen Pharmaceuticals came down July 1 after two weeks of trial before Philadelphia Court of Common Pleas Judge Paula Patrick. The largest Risperdal-related award to come down in Philadelphia had previously been a $2.5 million award that a jury handed up in February 2015.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
